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Abstract
Background: Staphylococcus aureus in its biofilm form has been associated with recalcitrant chronic rhinosinusitis with
significant resistance to conventional therapies. This study aims to determine if liposomal-encapsulation of a precursor of
the naturally occurring antimicrobial nitric oxide (NO) enhances its desired anti-biofilm effects against S. aureus, in the hope
that improving its efficacy can provide an effective topical agent for future clinical use.
Methodology: S. aureus ATCC 25923 biofilms were grown in-vitro using the Minimum Biofilm Eradication Concentration
(MBEC) device and exposed to 3 and 60 mg/mL of the NO donor isosorbide mononitrate (ISMN) encapsulated into different
anionic liposomal formulations based on particle size (unilamellar ULV, multilamellar MLV) and lipid content (5 and 25 mM)
at 24 h and 5 min exposure times. Biofilms were viewed using Live-Dead Baclight stain and confocal scanning laser
microscopy and quantified using the software COMSTAT2.
Results: At 3 and 60 mg/mL, ISMN-ULV liposomes had comparable and significant anti-biofilm effects compared to
untreated control at 24 h exposure (p = 0.012 and 0.02 respectively). ULV blanks also had significant anti-biofilm effects at
both 24 h and 5 min exposure (p = 0.02 and 0.047 respectively). At 5 min exposure, 60 mg/mL ISMN-MLV liposomes
appeared to have greater anti-biofilm effects compared to pure ISMN or ULV particles. Increasing liposomal lipid content
improved the anti-biofilm efficacy of both MLV and ULVs at 5 min exposure.
Conclusion: Liposome-encapsulated ‘‘nitric oxide’’ is highly effective in eradicating S. aureus biofilms in-vitro, giving great
promise for use in the clinical setting to treat this burdensome infection. Further studies however are needed to assess its
safety and efficacy in-vivo before clinical translation is attempted.
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Introduction
The battle against bacterial infections persists despite discoveries
of new and broader spectrum antibiotics. Over use of antibiotics
promotes the emergence of drug-resistant strains which makes
successful treatment even more challenging. Thus the global quest
for better and more efficacious antimicrobial agents continues.
Staphylococcus aureus (S. aureus) remains one of the most commonly
known opportunistic pathogens colonizing up to 2 billion people
worldwide. Ranging from chronic skin infections[1] and allergic
dermatitis,[2] to osteomyelitis[3] and sepsis,[4] S. aureus has great
versatility in contributing to diseased states in both healthy and
immunocompromised individuals[5]. Its existence in biofilm form
has been well documented,[6,7] partially explaining the difficulty
in eradication and its ability to cause a repeated cycle of infection.
Encased in an extra-polymeric substance matrix which enhances
microbial survival and impairs antimicrobial penetration,[8]
bacterial biofilms require up to 1000x greater antibiotic dose for
effective treatment compared to their planktonic counterparts.[9]
This contributes to treatment failure and emphasizes the need for
the development of alternative antimicrobial treatment strategies.
In particular, the isolation of S. aureus biofilms in the sinuses of
patients with chronic rhinosinusitis (CRS) has been linked to
poorer clinical outcomes and disease prognosis[10–12], further
defining the importance of this microorganism in disease severity.
Although antibiotics initially improve patients’ signs and symp-
toms, recurrence after treatment cessation is often the case,
demonstrating the limitations of the use of antimicrobial
compounds.
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In the sinuses of healthy individuals, the endogenous gas nitric
oxide (NO) has been documented to be highly concentrated,
sometimes reaching maximum allowable air pollutant levels,[13]
while the levels found in CRS patients are significantly lower.[14–
16] NO has demonstrated antibacterial and antiviral proper-
ties[17], plays a role in innate immunity and mucociliary
clearance[18] and is thought to provide a significant contribution
to maintaining the balance of normal flora in non-diseased sinuses.
Recent evidence has shown NO to also have anti-biofilm effects
against a wide range of organisms[19], including S. aureus.[20] Its
natural occurrence in the body in conjunction with its antimicro-
bial properties gives it great potential for topical application
against S. aureus biofilm-associated infections, both within and
outside the confines of the paranasal sinuses.
Whereas high NO levels have been shown to have anti-biofilm
effects on established S. aureus biofilms, we have demonstrated that
low NO levels increase the quantity of a S. aureus biofilm
biomass.[21] The dualistic effect of NO on S. aureus biofilms
indicates that the desired anti-biofilm effects are critically
dependent on the NO concentration and exposure time.[21]
Therefore there is a need to improve NO’s formulation prior to
clinical application as a topical therapy. Isosorbide mononitrate
(ISMN), a clinically approved NO-donor, has a well-established
safety profile in a range of applications.[22,23] Conversely, a
number of liposome-based drugs are already clinically approved
thereby demonstrating safety for clinical use.[24,25] Liposomes
typically increase drug specificity, lessen the risk of adverse drug
reactions, decrease the required dose and prolong drug-release, all
ideal properties of a suitable topical anti-biofilm agent. In addition,
liposomes have been found to be effective in delivering antibiotics
and other therapeutics to various biofilms.[26,27] Importantly, the
inherent bactericidal and anti-biofilm effects of cationic and
anionic liposomes are well demonstrated.[28–30] This motivated
the design of a novel ISMN liposomal formulation towards the
development of a novel topical treatment against S. aureus biofilms
with potential clinical applications in S. aureus biofilm-associated
diseases such as CRS. We specifically aimed to determine the
synergistic anti-biofilm effects obtained with unilamellar and
multilamellar anionic liposomal (ULV and MLV respectively)
formulations of ISMN. To this end, anionic ULV and MLV
liposomes were prepared and their efficacy tested in vitro.
Methodology
Nitric oxide donor
99% pure grade ISMN (Bosche Sci, NB, New Jersey) was used
as the NO donor. ISMN was chosen for liposomal encapsulation
due to its well-documented side effect profile and its established
safety for human use in the field of cardiology.[22,23] Character-
ization of the anti-biofilm and anti-planktonic effects of the free
drug form was first performed. Since the maximum aqueous
solubility of ISMN was at 60 mg/mL, serial dilutions down to
concentrations of 3.75 mg/mL were tested for anti-biofilm effects.
CSF broth was used as the diluent to ensure that it was not the
absence of bacterial culture media that was causing the desired
effect. Anti-planktonic properties were obtained by reading the
optical density (OD) at 540 nm at the bottom of each well of the
challenge plate.
Culture and formation of S. aureus biofilms
A biofilm forming reference strain S. aureus American Type
Culture Collection (ATCC) 25923 was used to test against the
different liposomal-NO formulations. S. aureus culture and biofilm
formation was performed as previously described.[21] Briefly, a
single loop of S. aureus glycerol stock was defrosted at 37uC in 2 mL
of cerebrospinal fluid (CSF) broth (Oxoid, Australia) for 18–
24 hours under agitation. 1 loop of culture was then plated onto a
blood agar plate (Oxoid, Australia) and incubated for 18–24 hours
at 37uC, following which 1–2 bacterial colonies were immersed in
0.45% saline to create a 1 McFarland unit (MFU) solution (36108
colony forming units/mL). This solution was then diluted to 1:15
in CSF broth, 150 mL of which was pipetted into each well of a 96-
well plate of the Minimum Biofilm Eradication Concentration
(MBEC) biofilm-forming device (Edmonton, Canada).
The MBEC device was used as per manufacturer’s instructions.
The pegs suspended on the lid were immersed into the 96-well
plate containing the bacterial solution and incubated for 44 hours
at 35uC on a gyrorotary shaker (Ratek, Vic, Aus) at 70 rpm,
allowing the biofilms to form on each peg’s surface.
Liposomal preparation
Anionic liposomes were prepared containing egg lecithin:dipal-
mitoylglycero-phosphoglycerol (DPPG) at 4:1 mol ratio. The
required amount of lipids was weighed into a 25 ml round bottom
flask and dissolved in 5 ml of chloroform. The chloroform was
slowly removed under reduced pressure using a Buchi rotary
evaporator (Buchi, Germany) to deposit a thin film of dry lipid on
the inner wall of the flask. The dry lipid film was hydrated with
5 ml of blank phosphate-buffered saline (PBS) solution or PBS
solution containing either 3 mg/ml or 60 mg/ml of ISMN for at
least 1.5 hours at a temperature of 5uC above the phase transition
temperature of the main lipid to obtain the MLV vesicles. ULV
were produced from MLVs by extrusion through 800 nm, 400 nm
and 200 nm pore size polycarbonate membranes in a Lipex 10 ml
Thermobarrel Extruder (Burnaby, BC Canada). In the anti-
biofilm activity studies, freshly prepared ULV and MLV ISMN
liposomal formulations were used without purification. The latter
approach was selected to increase the translational potential of the
proposed ISMN liposomal formulations.
Liposome Characterization
Particle Size Analysis. The particle size of the blank
liposomes and ISMN-loaded liposomes were characterised using
a dynamic light scattering (DLS) technique which has a size
detection range of 0.6 nm to 6 mm (Malvern Zetasizer Nano ZS,
UK). Liposomes were diluted 100-fold with 10 mM sodium
chloride (NaCl) aqueous solution prior to measurement at 25uC.
Water (refractive index = 1.33) was used as the dispersant in the
DLS analysis. A typical liposome refractive index of 1.45 was
used.[31] Size distribution results are expressed as the z-average
diameter (i.e. the intensity-weighted mean hydrodynamic diame-
ter) together with the polydispersity index (PDI) indicating the
width of the size distribution.
Determination of Zeta-potential. Liposomes were diluted
100-fold with 10 mM NaCl aqueous solution prior to the
measurement of zeta potentials. Zeta potentials were determined
by a using phase analysis light scattering (PALS) technique
(Malvern Zetasizer Nano ZS, UK) at 25uC, with the detection
limit of 5 nm to 10 nm particles. The mean zeta potential was
computed based on the electrophoretic mobility (i.e. the ratio of
the velocity of particles to the field strength) by applying the
Smoluchowski or Huckel theories.
Determination of drug encapsulation efficacy. Liposomes
were ultra-centrifuged at 30,000 rpm at 4uC for one hour. The
supernatant was taken and diluted with mobile phase and analysed
by high performance liquid chromatography (HPLC) to determine
the amount of free drug (Cfree). The pellet phase was rehydrated in
1 mM PBS. 0.2% Triton X-100 was added to break the
ISMN-Loaded Liposomes S. aureus Biofilms
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phospholipid structure and free the entrapped drug. The mixture
was sonicated (30 min) and centrifuged at 20,000 rpm for 30min.
The supernatant was taken, diluted and analysed by HPLC to
determine the amount of encapsulated drug (Cencapsulated). The







HPLC Analysis of ISMN
An HPLC method employing UV detection was used for
quantification of ISMN-containing samples (Shimadzu, Japan).
Chromatographic separation was performed on a LiChrospher RP
C18 column (5 mm, 4.6 mm ID6150 mm, Grace Davison
Discovery Science, Rowville, VIC) at a detection wavelength of
196 nm. The mobile phase was a mixture of methanol and water
(20:80 v/v), eluded at a flow rate of 1.5 ml/min. The sample was
injected at a volume of 50 ml at 40uC. The average retention time
was 3.4 min; detection limit of the method was 15 ng/ml. The
linearity range of the method used was 0.1–10 mg/ml with an R2
(correlation coefficient) value of 0.998. Within-day precision was
,3% and between-day precision was ,4%.
Exposure of S. aureus biofilms to the Liposome-
encapsulated ISMN
All liposomal experiments were repeated twice. The S. aureus
biofilm-coated pegs prepared using the MBEC device were
washed for 1 minute in 1x PBS to remove planktonic bacteria
and exposed to a challenge plate containing 180 mL of the
liposomal test agent added with 20 mL of 0.4 mM L-Arginine
(Musashi, Vic Aus) to mimic a bacterial culture state[32] for
24 hours at 37uC. Based on these results, the liposomal
formulations with the best anti-biofilm effects were selected and
tested at a shorter exposure time of 5 minutes, chosen to better
simulate the rapid exposure time of topical douching into the
sinuses. After 5 minutes of exposure to the challenge plate, the
pegs were re-immersed into a new 96-well plate containing 180 mL
of CSF broth with 20 mL of 0.4 mM L-Arginine and incubated for
24h.
Biofilm Imaging and Quantification
After treatment exposure, the pegs were washed twice in 0.9%
NaCl for 1 minute and 10 seconds respectively to remove
planktonic bacteria as per manufacturer’s instructions. These were
then fixed in 5% glutaraldehyde (Sigma Aldrich, St Louis MO) for
45 minutes, followed by a repeat wash in 0.9% NaCl for 10
seconds to remove excess fixative. The pegs were then individually
placed in 1 mL sterile milliQ water (Millipore, Billerica, MA)
containing 1.5 mL each of the LiveDead Baclight stains (Invitrogen
Molecular Probes, Vic Aus) Syto 9 and propidium iodide and
incubated on a rotating mixer at 10 rpm (Pelco, CA USA) in the
dark at room temperature for 15 minutes. The pegs were again
rinsed in 0.9% NaCl for 10 seconds and individually mounted on
cover slips for viewing under the Leica TCS SP5 confocal
scanning laser microscope (Leica Microsystems, Wetzlar, Ger-
many).
2 representative z-stacks each containing 120 +/– 5 serial
images set at 0.7 mm distance between 2 images were obtained per
peg. Biofilm quantification of each z-stack was then calculated
using the COMSTAT 2 software.[33]
Statistical Analysis
Graphpad Prism 5.0 (San Diego Ca) was used to calculate one-
way analysis of variance (ANOVA) when comparing biofilm
biomass of more than 2 treatment groups with Bonferroni multiple
comparisons (95% confidence interval) as post hoc test using the R
statistical software (R Foundation for statistical computing,
Vienna, Austria). Unpaired t-test was used to compare 2 groups
for the anti-biofilm effects of the pure drug ISMN. A p value of
,0.05 was considered statistically significant.
Results
Characterization of Liposomes
Anionic liposomes were prepared from Egg lecithin and DPPG
(4:1 molar ratio) using the standard thin film hydration method.
ULV liposomes were prepared from MLV’s using standard
extrusion. The physicochemical properties of the samples, namely
hydrodynamic diameter and zeta-potential, were obtained using
dynamic light scattering and are presented in Table 1. The
average hydrodynamic diameter of the as prepared MLV was
692 nm (PdI = 0.7). After membrane extrusion, ULV liposomes
were obtained with an average hydrodynamic diameter of 351 nm
(PdI = 0.6). The incorporation of ISMN during the hydration step
had little effect on the size of the liposomes, although a small
reduction was observed for the ISMN loaded MLV liposomes
(536 nm, PdI= 0.8) and a small increase was observed for the
ISMN loaded ULV liposomes (384 nm, PDI= 0.2). The zeta
potential was measured in 1022 M NaCl and as expected all
liposomal preparations displayed negative potentials. The zeta
potential values have been shown to be sufficient with excellent
colloidal stability.
Next the ISMN encapsulation efficiency was determined using
HPLC at two lipid concentrations, 5 mM and 25 mM. As
expected, the encapsulation efficiency was higher at higher lipid
concentrations for both ULV (1.3% at 5 mM vs. 6.3% at 25 mM)
and MLV (1.5% at 5 mM vs. 10.7% at 25 mM) liposomes (Table
2), while the increase in the lipid concentration had no significant
impact on the particle size.
Anti-biofilm and anti-planktonic effects of ISMN (free-
drug)
There was variability of biofilm growth of the untreated control
pegs across all experimental runs. These findings are similar to our
previous in-vitro biofilm studies,[21] and is attributed in part to
the stochastic process of biofilm development despite maintaining
constant growth conditions.[33] One-way ANOVA failed to show
statistical significance when comparing all treatment groups. A
global overview however, shows that biofilm growth at the lowest
ISMN concentration of 3.75 mg/mL was increased, compared to
the untreated control peg. (Figure 1) The unpaired t-test was then
used to determine if statistical significance was present when
comparing 2 groups. There was still no statistical significance
between the 3.75 mg/mL ISMN vs. untreated control (unpaired t-
test, p = 0.21). However, subsequent and increasing concentra-
tions of ISMN showed anti-biofilm effects, resulting in an almost
complete eradication at 60 mg/mL ISMN dose with statistical
significance (unpaired t-test vs. control, p = 0.024). This paradox-
ical pattern of enhanced biofilm growth at low NO concentrations
and anti-biofilm effects at higher concentrations is consistent with
findings from our previous studies using the NO donor
DetaNONOate.[21] The lowest ISMN concentration with statis-
tically significant anti-biofilm effects compared to the untreated
control was at 15 mg/mL (unpaired t-test vs. control, p = 0.025).
ISMN-Loaded Liposomes S. aureus Biofilms
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The anti-planktonic effects were also tested in the free-drug
form to completely characterize ISMN’s antibacterial effects in
order to obtain the best possible dose for liposomal encapsulation.
Planktonic growth is shown to be inversely proportional to ISMN
concentrations with the greatest anti-planktonic effect at 60 mg/
mL (One way ANOVA, p= ,0.0001). Figure 1 summarizes
these findings.
Anti-biofilm efficacy of ISMN liposomal formulations at
24-hour exposure
To establish the anti-biofilm potential of the ISMN-Liposomal
formulations, anionic ULV liposomes prepared with different
ISMN doses (3 mg/mL and 60 mg/mL) were tested using initially
a contact time of 24 hours. Their anti-biofilm activity was
compared to untreated control pegs (S. aureus biofilms grown for
44 hours on pegs immersed in pure CSF broth), corresponding
ULV blanks, and liposome-free treated control of pure drug
60 mg/mL ISMN.
The results are summarized in Figure 2. One-way ANOVA
using Bonferroni comparisons test showed that there was a
significant decrease in biofilm biomass in pegs treated with both
the 3 mg/mL ISMN and 60 mg/mL ISMN ULV liposomal
formulations when compared to their corresponding untreated
control (respectively 190 fold decrease– 0.024 mm3/mm2 vs.
untreated control 4.56 mm3/mm2 p= 0.0013; and 2126 fold
decrease– 0.005 mm3/mm2 vs. untreated control of 10.63 mm3/
mm2, p= 0.003). Blank ULV liposomes also resulted into a
significant decrease in the biofilm biomass (152 fold decrease;
0.03 mm3/mm2 for 3 mg/mL ISMN p= 0.0013; and 2650 fold
decrease; 0.004 mm3/mm2 for 60 mg/mL ISMN, p= 0.003
respectively) compared to the untreated control. Comparing
ULVs incorporating either 3 or 60 mg/mL ISMN vs. their
corresponding blanks however showed no statistical significance
using unpaired t-test (p. 0.05). In agreement with our mechanistic
study, ISMN alone had a very strong negative effect on the biofilm
biomass at a dose of 60 mg/mL (26,575 fold decrease;
0.0004 mm3/mm2 p= 0.003). There was no significant difference
in anti-biofilm effects of ISMN alone compared to ULV at 3 or
60 mg/mL ISMN and their blanks (p. 0.05). These results
indicate that both ISMN alone, ULV alone and both compounds
combined diminish S. aureus biofilms in vitro after 24 hours.
Effects of ISMN-liposome formulations in short term (5
minutes) exposure
Based on these results, we wanted to see if the anti-biofilm
effects of the above formulations were maintained at a time of 5
min incubation mimicking the shorter contact time of a topical
wash into the nose and paranasal sinuses. One-way ANOVA
showed a significant decrease in biofilm biomass at 3 mg and
60 mg/mL ISMN ULV liposomes compared to untreated control
(respectively 33 fold at 0.25 mm3/mm2, p= 0.008; and 922 fold at
0.009 mm3/mm2, p= 0.007 vs. untreated control of 8.3 mm3/
mm2). Blank ULV liposomes also significantly reduced the S. aureus
biofilm biomass compared to the untreated control (15 fold,
0.55 mm3/mm2 vs. 8.3 mm3/mm2, p= 0.009). Although the results
did not reach statistical significance, ISMN-liposomal formulations
showed stronger anti-biofilm effects than blank liposomes,
especially at the higher ISMN dose. The 60 mg/mL liposomal
formulation had a greater anti-biofilm effect than the liposome-
free ISMN at the same dose (922 fold; 0.009 mm3/mm2 for 60 mg/
ml ISMN ULV vs. 69 fold; 0.12 mm3/mm2 for 60 mg/ml ISMN
alone, p. 0.05). (Figure 3) Together, these results demonstrate
the anti-biofilm effects of ULV liposomes, ISMN free drug and
ISMN-ULV liposomes also at short (5 minutes) exposure times, in
particular for higher (60 mg/ml) ISMN concentrations.
Building on the above results, 60 mg/mL ISMN liposomal
formulations were now selected to investigate the anti biofilm
efficacy of this approach at a 5 min incubation duration altering
lipid composition. A non-statistically significant decrease was
observed in the biofilm biomass when treated with the 60 mg/mL
ISMN ULV liposomal formulation at a 5 mM lipid concentration
compared to the blank ULV liposome at the same lipid
concentration (1.1 mm3/mm2 vs. 1.7 mm3/mm2, p. 0.05). How-
ever, both groups showed a significantly reduced biomass
compared to the untreated control (4.4 mm3/mm2, p= 0.01 for
ULV loaded and p= 0.04 for ULV Blank) but no significant
difference compared to the ISMN treated group (1.1 mm3/mm2).
Next a 60 mg/ml ISMN–ULV liposomal formulation at 25 mM
lipid concentration was tested. Unlike the lower lipid concentra-
tions, both blank ULV and ISMN ULV liposomal formulations
significantly reduced the biofilm biomass (1.1 mm3/mm2, p= 0.01
for Blank and 0.6 mm3/mm2 for loaded, p = 0.004) compared to
the untreated control. No significant inhibiting effects were
however observed compared to the pure-drug ISMN control.
Although no statistical difference was attained between the ISMN
liposomal formulations at 5 mM and 25 mM, the higher lipid
concentration tended to reduce the biofilm biomass to a greater
extent than the lower concentration counterpart (0.6 mm3/m
25 mM vs. 1.1 mm3/mm2 for 5 mM p.0.5).
Next a 25 mM lipid MLV formulation loaded with 60 mg/mL
ISMN was tested and compared to the ULV formulations and
Table 1. Particle size and zeta-potential of the prepared anionic liposomes.
Liposome Lipid Composition Hydrodynamic diameter (nm) Zeta Potential (mV)
MLV ULV MLV ULV
Blank Egg lecithin : DPPG 4 : 1 692 351 –27.7 –38.5
ISMN 536 384 –32.9 –19.6
ISMN: isosorbide mononitrate; MLV: multilamellar; ULV: unilamellar
doi:10.1371/journal.pone.0092117.t001
Table 2. Drug encapsulation efficiency of anionic liposomes
loaded with 60 mg/mL of isosorbide mononitrate.
Liposome En%
MLV ULV
Ani-ISMN-5 mM 1.4760.32 1.3060.19
Ani-ISMN-25 mM 10.7361.51 6.3460.19
MLV: multilamellar; ULV: unilamellar; En%: percentage of drug encapsulated.
doi:10.1371/journal.pone.0092117.t002
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untreated and pure-drug ISMN controls. As shown in Figure 4,
the 60 mg/mL ISMN loaded MLV formulation resulted into a
significant decrease in the biofilm biomass in comparison to the
untreated control (0.003 mm3/mm2 vs. 4.4 mm3/mm2, p= 0.002).
Although the MLV formulation had stronger anti-biofilm effects
compared to its ULV counterpart at similar ISMN and lipid
concentration (0.003 mm3/mm2 for MLV vs. 0.6 mm3/mm2 for
ULV) the results did not reach statistical significance. This was the
same when comparing the MLV formulation with the pure-drug
ISMN (0.003 mm3/mm2 vs. 1.14 mm3/mm2). The blank MLV also
resulted in a biofilm biomass decrease when compared to the
untreated control (1.4 mm3/mm2 vs. 4.4 mm3/mm2, p= 0.02).
Although there was a decrease in biofilm biomass with the
encapsulated 60 mg/mL ISMNMLV formulation compared to its
blank (0.002 mm3/mm2 vs. 1.4 mm3/mm2), the results did not reach
statistical significance with the Bonferroni test. Figure 5 shows
representative 3D projection images of S. aureus biofilms exposed to
the MLV liposomes.
Discussion
In this study, the anti-biofilm effect of liposomal-formulations of
ISMN against S. aureus was demonstrated. In vitro experiments
indeed showed that short exposure times mimicking nasal flush
induced a strong reduction in the biofilm biomass. These also
showed that modification of liposome size and lipid content
dramatically alters its efficacy. Our results may guide which
liposomal characteristics are critical in the formulation of
liposomes encapsulating compounds for optimal topical delivery
to S. aureus biofilms.
There is a vast existence of S. aureus-related infections where
effective anti-biofilm therapy is needed. Infections of the skin,[1]
bone,[3] heart (endocarditis),[34] sinuses[7,11] and device-related
infections (catheters, implantable prosthetics)[35,36] could be
Figure 1. Dose-response of pure ISMN on S. aureus biofilm biomass (A) and planktonic cell growth (B). 4.64 is the biofilm biomass at
3.75 mg/mL ISMN concentration. ISMN: Isosorbide mononitrate. Data represents Mean +/– SD of a duplicate experiment. *, P,0.05; **, P,0.01, ***,
P,0.001 compared to untreated control; Two-tailed t test.
doi:10.1371/journal.pone.0092117.g001
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targeted with specifically designed liposomes encapsulating the
appropriate drug dose. Liposomes, with their phospholipid bilayer,
can be modified to deliver drugs to specific physiologic targets to
obtain the desired therapeutic efficiency.[37] Alteration of the lipid
composition and concentration in the bilayer has been demon-
strated in past studies to have significant effects on the extent of
adsorption into S. aureus biofilms.[38] These liposomal properties
thus change the effectiveness of the encapsulated drugs in
performing their action. Given the degree of difficulty of biofilm
matrix penetration by topical antimicrobials, which originates in a
combination of physical and metabolic barriers[39], ensuring that
highly efficient drug doses diffuse into and reach embedded
bacterial cells, is key for effective biofilm eradication. Bacterial
properties such as cell wall hydrophobicity have also been shown
to affect liposome penetration and hence drug mobility through
the biofilm matrix.[40] In this study, the S. aureus biofilm-liposome
interaction is yet to be explored and further characterization of
this relationship is required.
We chose to use anionic liposomes by virtue of their well-
documented anti-biofilm properties against S. aureus,[41,42] with
an aim to obtain a synergistic effect with the NO donor ISMN and
improve overall efficacy. Furthermore, a comparison of ULV and
MLV formulations was carried out. ULV liposomes were
demonstrated to have anti-biofilm effects even without the
encapsulated NO donor and these effects were more pronounced
compared to their MLV counterparts. Although beyond the scope
of this study, many factors may alter this antimicrobial effect of
bare liposomes. A direct interaction of the liposome with the
bacterial cell wall may play a role in better biofilm penetra-
tion.[43] Bacterial cell wall properties, different for gram positive
and negative bacteria, have been shown to be an important factor
in nanoparticle penetration of biofilm matrix.[44] Changing
expression of cell-wall proteins can completely switch bacterial
Figure 2. Effects of ISMN, ULV Blank and ISMN-ULV liposomes on S. aureus biofilm biomass after 24 hours. The numbers above the bar
represents the biofilm biomass of the untreated controls. ULV: Unilamellar liposome; ISMN: Isosorbide mononitrate. Data represents Mean +/– SD of a
duplicate experiment. A replicate experiment showed the same trend. *, P,0.05; **, P,0.01, ***, P,0.001 vs untreated control; Bonferroni’s multiple
comparisons test.
doi:10.1371/journal.pone.0092117.g002
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surface properties from hydrophilic to hydrophobic without
altering biofilm structure, thus significantly altering susceptibility
of bacteria to nanoparticles[45] such as liposomes. Thus,
characterization of the physicochemical properties of the targeted
bacteria is needed to develop specifically designed liposomes in
order to produce desired anti-biofilm results. Although the
liposomal-bacterial interaction was not characterized in detail in
this in-vitro study, a clearer description of this interaction is
therefore warranted prior to in-vivo and clinical application.
When comparing the ISMN liposomal formulations of 5 mM
and 25 mM lipids, liposomes of higher lipid concentration tended
to be superior in reducing the biofilm biomass in comparison to
the lower concentration counterpart. In addition, according to the
encapsulation study, the drug encapsulation efficiency in liposomes
of high lipid concentration was at least 5-fold higher than that of
the lower concentration counterpart. It is likely that the
encapsulation efficiency plays a significant role in defining the
extent of drug delivery to the biofilm. In this study, it was
Figure 3. Effects of ULV Blank liposomes, ISMN-ULV liposomes and ISMN on S. aureus biofilm biomass after 5 minutes. The number
above the bar represents the biofilm biomass beyond the y-axis scale. ULV: Unilamellar liposome; ISMN: Isosorbide mononitrate. Data represents
Mean +/– SD of a duplicate experiment. *, P,0.05; **, P,0.01, ***, P,0.001 compared to untreated control; Bonferroni multiple comparisons test.
doi:10.1371/journal.pone.0092117.g003
Figure 4. Biofilm biomass of S. aureus ATCC 25923 exposed for 5 minutes to MLV liposomes of 25 mM lipid composition. Data shows
MLV Blank and MLV liposomes encapsulating 60 mg/mL of the NO donor ISMN. MLV: Multilamellar liposome, ISMN: Isosorbide mononitrate. Data
represents Mean +/– SD of a duplicate experiment. *, P,0.05; **, P,0.01, ***, P,0.001; Bonferroni multiple comparisons test.
doi:10.1371/journal.pone.0092117.g004
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deliberately chosen not to purify the ISMN liposomal formulations
towards facilitating their translational uses against CRS. However,
this approach further increased the complexity of the system from
a structure-activity point of view since both free ISMN and
encapsulated drug is present in the formulation. Further mecha-
nistic understanding of how the liposomal formulations affect the
delivery of the NO donor to the biofilm is required, as well as
elucidating the how the synergistic role of liposomes and ISMN in
reducing the biofilm biomass.
Although ULV liposomes have been to date the preferred
clinical option considering their optimal pharmacokinetics in
blood, in the context of topical treatment such as in CRS, MLV
liposomes present many advantages over their ULV counterparts.
They are indeed easier to manufacture, and are more stable with
longer storage in liquid form. MLV liposomes will thus most likely
offer a more straightforward translational path to the creation of a
topical sinus rinse. In this study, it was demonstrated that MLV
liposomes with greater lipid composition are comparable to ULV
liposomes in terms of anti-S. aureus biofilm effects encapsulating the
same ISMN concentration of 60 mg/mL. Thus in future in vivo
studies, MLV liposomes will most likely be the approach in the
conversion to clinical application in the context of CRS.
Providing alternative antimicrobial agents that are safe and
effective, will hopefully contribute to decreasing antibiotic use, and
consequently reduce the risk of developing drug resistance. With
MRSA emerging as a global concern and a shift in pharmaceutical
interest away from antibiotic therapy due to lesser profitabili-
ty,[46] the development of novel antimicrobials is urgently needed.
Despite the necessity to further improve the proposed liposomal
ISMN formulations and characterize their mechanisms of action,
the identification of the efficacy of high-lipid anionic MLV
liposomes proves an important first step in the successful topical
utilization of liposomal-encapsulated nitric oxide to treat S. aureus
biofilm infection in CRS.
Conclusion
Liposomal formulation of ISMN has significant anti-biofilm
effects against S. aureus, showing greatest efficacy with higher lipid
content in both ULV and MLV systems. Future in-vivo studies are
required however, to determine their safety prior to attempts at a
topical clinical application.
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